PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Rhea-AI Summary

PatentVest (MDBH) announced on March 11, 2026 the completion of a strategic intellectual property engagement with Porosome Therapeutics to evaluate and strengthen its IP portfolio for secretion-restoration therapeutics.

PatentVest delivered an IP portfolio audit, global patent landscape analyses, competitive benchmarking, and partner assessment, and found Porosome Therapeutics has a distinct position in structural porosome reconstitution. Porosome plans additional filings covering organoid models, novel peptides, and small-molecule innovations to expand its IP estate.

Positive

• Completed strategic IP engagement with PatentVest on March 11, 2026
• PatentVest delivered a comprehensive IP audit, landscape analysis, benchmarking, and partner assessment
• Porosome is expanding filings to cover organoid models, novel peptides, and small-molecule innovations

Negative

• None.

News Market Reaction – MDBH

-4.00%

1 alert

-4.00% News Effect

On the day this news was published, MDBH declined 4.00%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.82 Vol: Volume 1,210 is well belo...

low vol

$2.82 Last Close

Volume Volume 1,210 is well below 20-day average of 7,022 (relative 0.17). low

Technical Price 3.0001 is trading below the 200-day MA of 3.69.

Peers on Argus

Sector scanner shows 4 peers in momentum: 2 moving up and 2 moving down, with no...

2 Up 2 Down

Sector scanner shows 4 peers in momentum: 2 moving up and 2 moving down, with no same-day peer headlines. This points to mixed but active sector dynamics rather than a clear, unified move.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	GLP-1 IP report	Positive	-1.3%	PatentVest report on GLP-1 patent race and market opportunity.
Feb 02	Board changes	Neutral	-3.1%	Board transition with new director to support scaling strategy.
Jan 14	Space IP report	Positive	+6.7%	PatentVest report on IP across the $1.8 trillion space economy.
Nov 20	Q3 2025 update	Positive	-3.4%	Operational update including private placement and planned IPO.
Nov 11	Earnings call setup	Neutral	+4.5%	Announcement of upcoming Q3 2025 business update webinar.

Pattern Detected

Recent MDBH news, including reports and corporate updates, has shown mixed price reactions, with several informative or strategic releases met by modest declines or only brief strength.

Recent Company History

Over the last six months, MDBH has issued multiple updates tied to its PatentVest platform and broader corporate strategy. On Nov 11, 2025, it announced plans for a Q3 2025 business update webinar, followed by a Q3 operational update on Nov 20, 2025 that highlighted a planned $16.8 million private placement and a $20 million IPO. In January and February 2026, PatentVest released thematic IP reports and the company disclosed board transitions. Price reactions to these events ranged from declines of a few percent to a 6.71% gain, indicating no consistent pattern of market response.

Market Pulse Summary

This announcement highlights PatentVest’s role in validating Porosome Therapeutics’ IP position in s...

Analysis

This announcement highlights PatentVest’s role in validating Porosome Therapeutics’ IP position in secretion restoration technologies, underscoring a focus on structural porosome reconstitution and ongoing patent filings around organoid models and small molecules. For MDBH, it reinforces the use of its PatentVest platform to underwrite emerging biotech stories. Investors may track how often such IP engagements translate into financings, new client mandates, or reported fee income in future filings and corporate updates.

Key Terms

porosome reconstitution platforms, supramolecular porosome complex, cellular secretion, organoid models, +3 more

7 terms

porosome reconstitution platforms medical

"Porosome Therapeutics is advancing Porosome Reconstitution Platforms (PRPs), a novel approach"

Porosome reconstitution platforms are laboratory systems that rebuild the tiny cellular structures (porosomes) responsible for releasing molecules from cells, so researchers can study and manipulate secretion in a controlled setting. For investors, these platforms matter because they can accelerate discovery of new drugs, improved biologic manufacturing or diagnostic tools by replicating a fundamental cell process outside the body—think of them as test rigs that let scientists prototype and validate treatments before costly clinical steps.

supramolecular porosome complex medical

"designed to reconstruct the supramolecular porosome complex, the universal docking and fusion"

A supramolecular porosome complex is a multi‑molecule structure in the cell membrane that forms the actual opening through which cells release packets of chemicals, like hormones or neurotransmitters. For investors, it matters because understanding or targeting these complexes can lead to new drug mechanisms, diagnostic tests, or delivery technologies—think of it as a biological valve whose control could change how therapies are designed or delivered.

cellular secretion medical

"fusion machinery responsible for cellular secretion."

Cellular secretion is the process by which living cells release molecules—such as proteins, hormones or enzymes—into their surroundings, like a factory sending out packages that influence nearby tissue or the whole body. For investors, secretions matter because they can be the active ingredients or biomarkers behind drugs, diagnostics and safety signals; understanding what cells secrete helps assess a therapy’s mechanism, potential market value and regulatory risks.

organoid models medical

"new filings covering organoid models, novel peptides, and small-molecule innovations"

Organoid models are tiny, lab-grown versions of human tissues created from stem cells that mimic the structure and behavior of real organs. They act like miniature crash-test dummies for drugs and therapies, letting researchers see how a human tissue might respond before expensive clinical trials, which can reduce development risk, speed decision-making and make investment outcomes more predictable. For investors, organoids signal potential cost savings, clearer clinical signals and new licensing or diagnostics opportunities.

small-molecule medical

"organoid models, novel peptides, and small-molecule innovations designed to strengthen"

A small-molecule is a low-weight chemical compound designed to affect biological processes, often able to enter cells and be taken as a pill or simple injection. Investors watch small-molecule programs because they usually cost less and move faster through development than large biologics, have different manufacturing and patent dynamics, and face distinct competition and market-size implications—think of them as compact tools versus larger, more complex machines in a drugmaker’s toolbox.

patent landscape analyses regulatory

"conducted a comprehensive IP portfolio audit, global patent landscape analyses, competitive"

Patent landscape analyses are systematic reviews of patent filings and related public records that map who owns which technologies, where innovation is concentrated, how broad protections are, and how patent activity has changed over time and across regions. For investors they act like a technology map and risk report — revealing a company’s competitive strengths, potential legal or freedom-to-operate risks, and gaps that signal opportunities or threats, helping assess whether a business’s innovations are defensible and likely to sustain value.

intellectual property portfolio regulatory

"strengthening Porosome Therapeutics’ intellectual property portfolio to support future"

A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.

AI-generated analysis. Not financial advice.

Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) -- PatentVest announced the completion of a strategic intellectual property engagement with Porosome Therapeutics, Inc., a biotechnology company developing a first-in-class therapeutic platform designed to restore cellular secretion mechanisms.

The collaboration focused on evaluating and strengthening Porosome Therapeutics’ intellectual property portfolio to support future partnerships, commercialization efforts, and capital strategy initiatives. PatentVest conducted a comprehensive IP portfolio audit, global patent landscape analyses, competitive benchmarking, and strategic partner assessment.

Porosome Therapeutics is advancing Porosome Reconstitution Platforms (PRPs), a novel approach to restore cells' native secretory machinery. Unlike traditional therapies that suppress or modulate secretion pathways, the technology is designed to reconstruct the supramolecular porosome complex, the universal docking and fusion machinery responsible for cellular secretion.

The strategic analysis confirmed that Porosome Therapeutics occupies a distinct and defensible intellectual property position within the emerging field of secretion restoration technologies, with minimal direct competitive overlap in structural porosome reconstitution.

"The intellectual property landscape in cellular therapeutics is incredibly crowded, but Porosome Therapeutics has successfully carved out a highly defensible white space," said Will Rosellini, CIPO of PatentVest. "Our analysis clearly shows that by focusing on the structural reconstitution of the porosome complex rather than traditional secretion modulation, they have secured a foundational patent portfolio. This distinct IP moat positions them exceptionally well for high-value strategic partnerships and long-term commercial success."

“Working with PatentVest has provided valuable strategic insight into our intellectual property landscape and the broader competitive environment,” said Guillermo Marmol, CEO of Porosome Therapeutics. “Their analysis helped validate the strength of our IP portfolio and clarify how our platform is uniquely positioned within the field of secretion restoration technologies. This work supports our next phase of development as we pursue partnerships and expand our patent portfolio.”

As part of its ongoing innovation strategy, Porosome Therapeutics continues to expand its intellectual property portfolio with new filings covering organoid models, novel peptides, and small-molecule innovations designed to strengthen its proprietary platform further.

About Porosome Therapeutics

Porosome Therapeutics, Inc. is a biotechnology company developing therapies based on the restoration of cellular secretion mechanisms through Porosome Reconstitution Platforms (PRPs), with potential applications in diseases associated with dysfunctional secretion.

Work With PatentVest

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets. 

For more information or inquiries, please contact info@patentvest.com.

FAQ

What did PatentVest announce about its work with Porosome Therapeutics (MDBH) on March 11, 2026?

PatentVest completed a strategic intellectual property engagement with Porosome Therapeutics on March 11, 2026. According to PatentVest, the work included an IP audit, global patent landscape analyses, competitive benchmarking, and partner assessment to strengthen Porosome's IP position.

How does the PatentVest analysis affect Porosome Therapeutics' IP position and partnerships (MDBH)?

The analysis concluded Porosome occupies a distinct IP position in porosome reconstitution. According to PatentVest, this defensible position supports pursuit of high-value strategic partnerships and long-term commercialization opportunities.

What specific IP work will Porosome Therapeutics pursue after the PatentVest engagement (MDBH)?

Porosome plans additional patent filings covering organoid models, novel peptides, and small-molecule innovations. According to Porosome Therapeutics, these filings aim to strengthen and broaden its proprietary platform for secretion restoration.

What is the porosome reconstitution platform mentioned in the PatentVest announcement (MDBH)?

The porosome reconstitution platform seeks to restore cells' native secretory machinery rather than merely modulate secretion pathways. According to Porosome Therapeutics, the approach reconstructs the supramolecular porosome complex responsible for cellular secretion.

Does the PatentVest announcement disclose financial terms or funding related to the MDBH engagement?

No financial terms or funding details were disclosed in the announcement. According to PatentVest and Porosome Therapeutics, the release focused on the IP audit, landscape analysis, and planned patent filings rather than transaction values.